Spironolactone Ceva

RSS

Withdrawn

This medicine's authorisation has been withdrawn

spironolactone
MedicineVeterinaryWithdrawn

Spanish is available via eTranslation, the European Commission's machine translation service.

Translate to Spanish | Important information about machine translation

  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

The marketing authorisation for this product has been withdrawn due to the application of the sunset clause.

български (BG) (332.91 KB - PDF)

Ver

español (ES) (288.28 KB - PDF)

Ver

čeština (CS) (322.23 KB - PDF)

Ver

dansk (DA) (287.53 KB - PDF)

Ver

Deutsch (DE) (289.53 KB - PDF)

Ver

eesti (ET) (276.29 KB - PDF)

Ver

ελληνικά (EL) (335.21 KB - PDF)

Ver

français (FR) (289.25 KB - PDF)

Ver

hrvatski (HR) (307.68 KB - PDF)

Ver

latviešu (LV) (334.28 KB - PDF)

Ver

Malti (MT) (324.47 KB - PDF)

Ver

Nederlands (NL) (287.82 KB - PDF)

Ver

polski (PL) (380.69 KB - PDF)

Ver

português (PT) (288.12 KB - PDF)

Ver

română (RO) (482.45 KB - PDF)

Ver

slovenčina (SK) (324.97 KB - PDF)

Ver

slovenščina (SL) (318.42 KB - PDF)

Ver

suomi (FI) (285.73 KB - PDF)

Ver

svenska (SV) (287.15 KB - PDF)

Ver

Product information

български (BG) (936.84 KB - PDF)

Ver

español (ES) (457.64 KB - PDF)

Ver

čeština (CS) (695.23 KB - PDF)

Ver

dansk (DA) (443.55 KB - PDF)

Ver

Deutsch (DE) (456.17 KB - PDF)

Ver

eesti (ET) (460.88 KB - PDF)

Ver

ελληνικά (EL) (957.24 KB - PDF)

Ver

français (FR) (383.63 KB - PDF)

Ver

hrvatski (HR) (504.46 KB - PDF)

Ver

italiano (IT) (614.01 KB - PDF)

Ver

latviešu (LV) (750.12 KB - PDF)

Ver

lietuvių (LT) (673.01 KB - PDF)

Ver

magyar (HU) (1.07 MB - PDF)

Ver

Malti (MT) (774.79 KB - PDF)

Ver

Nederlands (NL) (445.92 KB - PDF)

Ver

polski (PL) (1.09 MB - PDF)

Ver

português (PT) (456.69 KB - PDF)

Ver

română (RO) (807.04 KB - PDF)

Ver

slovenčina (SK) (711.68 KB - PDF)

Ver

slovenščina (SL) (702.28 KB - PDF)

Ver

suomi (FI) (456.54 KB - PDF)

Ver

svenska (SV) (441.7 KB - PDF)

Ver

Íslenska (IS) (622.5 KB - PDF)

Ver

norsk (NO) (656.3 KB - PDF)

Ver
Latest procedure affecting product information:IAIN/0014
31/10/2012

български (BG) (299.51 KB - PDF)

Ver

español (ES) (219.22 KB - PDF)

Ver

čeština (CS) (262.67 KB - PDF)

Ver

dansk (DA) (227.42 KB - PDF)

Ver

Deutsch (DE) (218.75 KB - PDF)

Ver

eesti (ET) (221.16 KB - PDF)

Ver

ελληνικά (EL) (268.37 KB - PDF)

Ver

français (FR) (221.14 KB - PDF)

Ver

hrvatski (HR) (227.55 KB - PDF)

Ver

italiano (IT) (191.92 KB - PDF)

Ver

latviešu (LV) (256.74 KB - PDF)

Ver

lietuvių (LT) (210.34 KB - PDF)

Ver

magyar (HU) (210.45 KB - PDF)

Ver

Malti (MT) (250.85 KB - PDF)

Ver

Nederlands (NL) (228.06 KB - PDF)

Ver

polski (PL) (245.92 KB - PDF)

Ver

português (PT) (231.37 KB - PDF)

Ver

română (RO) (434.62 KB - PDF)

Ver

slovenčina (SK) (253.67 KB - PDF)

Ver

slovenščina (SL) (237.31 KB - PDF)

Ver

suomi (FI) (204.11 KB - PDF)

Ver

svenska (SV) (218.51 KB - PDF)

Ver

Íslenska (IS) (185.95 KB - PDF)

Ver

norsk (NO) (222.67 KB - PDF)

Ver

Product details

Name of medicine
Spironolactone Ceva
Active substance
spironolactone
International non-proprietary name (INN) or common name
spironolactone
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) code
QC03DA01

Pharmacotherapeutic group

Diuretics

Therapeutic indication

For use in combination with standard therapy (including diuretic support, where necessary) for the treatment of congestive heart failure caused by valvular regurgitation in dogs.

Authorisation details

EMA product number
EMEA/V/C/000105
Marketing authorisation holder
Ceva Santé Animale

10 avenue de la Ballastière
33500 Libourne
France

Opinion adopted
17/04/2007
Marketing authorisation issued
20/06/2007
Revision
7

Assessment history

This page was last updated on

Share this page